FIELD: chemistry.
SUBSTANCE: invention relates to a Nav1.8 inhibitor, which is 2,3-dihydroquinazoline compound of formula (XIV), where X4’, R41’, R42’, R43’ and R45’ are defined in the claims, or to its pharmaceutically acceptable salts, or its tautomeric forms. Also disclosed are pharmaceutical compositions and use thereof in a method of treating pain and/or a pain-related or associated disease, disorder or condition.
EFFECT: treating pain and/or a pain-related or associated disease, disorder or condition.
21 cl, 299 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMIDES OF CONDENSED PIPERIDINE AS MODULATORS OF ION CHANNELS | 2014 |
|
RU2741810C2 |
| 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | 2019 |
|
RU2830169C2 |
| 1-HYDROXYIMINO-3-PHENYL-PROPANES | 2011 |
|
RU2579114C9 |
| COMT INHIBITORS | 2013 |
|
RU2642779C2 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
| NOVEL COMPOUNDS OF SUBSTITUTED N-(3-FLUOROPROPYL)PYRROLIDINE, METHODS FOR PRODUCTION THEREOF AND THERAPEUTIC APPLICATION THEREOF | 2017 |
|
RU2742278C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
| PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | 2013 |
|
RU2646754C2 |
| TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
